|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis.
|
1333465 |
1992 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that p53 mutations occur in human endometrial carcinoma, although relatively infrequently, and that loss of the normal p53 allele does not necessarily occur with point mutation of the p53 gene in this tumor type.
|
1497800 |
1992 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Overexpression and mutation of p53 in endometrial carcinoma.
|
1540970 |
1992 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Sequencing analysis of the entire coding region revealed mutations changing the p53 amino acid composition in all six endometrial carcinoma cell lines tested (Ishikawa, Hecl-A, Hecl-B, KLE, RL95-2, and AN-3).
|
1660340 |
1991 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus.
|
1913680 |
1991 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis.
|
7567946 |
1995 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HER-2/neu, transforming growth factor alpha, and p53 proteins have all been associated with poor prognosis in women with endometrial cancer.
|
7585656 |
1995 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To compare the prognostic importance of certain molecular biologic characteristics (HER-2/neu and p53 gene overexpression, DNA ploidy, and the S-phase fraction) to standard clinical-pathologic factors used to predict survival in patients with endometrial carcinoma.
|
7724103 |
1995 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the p53 gene were detected in 5 of 38 endometrial carcinomas from Colorado (13%), including a single base substitution mutation in 3 cases (60%) and a deletion mutation in 2 cases (40%).
|
7856567 |
1995 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Several molecular-genetic alterations in endometrial cancers, including aneuploidy and aberrant expression of p53 and HER-2/neu, have been associated with poor prognosis.
|
7909491 |
1994 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Uterine papillary serous adenocarcinoma (UPSA) is a highly aggressive neoplasm with a great tendency for dissemination. p53 and c-erbB-2 immunoreactivity and DNA ploidy are considered to be indicators of prognosis for endometrial carcinomas.
|
7915964 |
1994 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_mouse |
Endometrial carcinogenesis induced by concurrent oral administration of ethylenethiourea and sodium nitrite in mice.
|
7955072 |
1994 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Consequently, p53 overexpression itself does not appear to be an independent prognostic factor in endometrial cancer, although a still larger sample of patient material would be required to assess this issue definitively.
|
8014010 |
1994 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Following these results, immunohistochemistry with the PAb monoclonal antibody may be safely used as a screening tool for the detection of mutated p53 in clinical samples of mammary and endometrial cancer, whereas it should be complemented with DNA analysis in cervix carcinoma.
|
8018409 |
1994 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Alterations of the retinoblastoma (Rb) gene were evaluated in nine primary endometrial adenocarcinomas that we had previously analyzed for the presence of Ki-ras activations and p53 alterations and in three endometrial carcinoma cell lines.
|
8105795 |
1993 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.
|
8156496 |
1994 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Similar to many other types of human cancers, ovarian and endometrial cancers that overexpress p53 protein contain mutations in conserved regions of the p53 gene.
|
8296829 |
1994 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
None of 117 endometrial hyperplasias were found to have mutations in the p53 gene, whereas mutations were seen in three of 30 (10%) endometrial cancers (p < 0.02).
|
8372881 |
1993 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A high frequency of allelic losses corresponding to the 17p13.3 region that contained the p53 gene sequence was also noted in human endometrial carcinoma.
|
8473053 |
1993 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results suggest that immunostaining of p53 is associated with the malignant phenotype, but does not correlate with the biological behavior of human endometrial carcinoma.
|
8517643 |
1993 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Mutation and LOH of the p53 gene are prognostic indicators in patients with endometrial carcinoma, suggesting that alterations of p53 may play an important role in the development of this cancer.
|
8630879 |
1995 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
|
8687148 |
1996 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Of 122 endometrial carcinomas, 33 (27%) showed overexpression of p53 in the nucleus and 66 (54%) in the cytoplasm.
|
8761370 |
1996 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Mutant p53 protein overexpression is defined in many human cancers, including endometrial carcinoma.
|
8826947 |
1996 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Cytoplasmic staining was observed with DO7 in 7% of breast and 5% of gastric carcinomas and with CM1 in 17% of breast and 54% of endometrial carcinomas. p53 gene mutation was found in 39% of colorectal, 28% of breast, 13% of endometrial, and 25% of gastric cancers.
|
8892589 |
1996 |